Zimberelimab

Phase 3

Arcus Biosciences, Inc. (RCUS)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

RCUSPhase 2$3.4B

Zimberelimab Phase 2 Est. Readout

Zimberelimab• Non Small Cell Lung Cancer33

Dec 2026~Estimated

CT.gov

00%

Oct '26

RCUSPhase 2$3.4B

Zimberelimab Phase 2 Est. Readout

Zimberelimab• Non Small Cell Lung Cancer30

Oct 2026~Estimated

CT.gov

00%

Competitive Landscape

14 competitors in Non Small Cell Lung Cancer

REGNLibtayo

Phase 3

MRKArm A: Pemetrexed Cisplatin

Phase 2

SNYoxaliplatine / gemcitabine / Vinorelbine

Drug Information

Target Indication

Non Small Cell Lung Cancer

Clinical Trial

NCT04736173

Last updated: 12/29/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

RCUS

Arcus Biosciences, Inc.

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

QuemliclustatPhase 3

Gastrointestinal Tract Malignancies

CasdatifanPhase 3

Metastatic Clear Cell Renal Cell Carcinoma

DomvanalimabPhase 3

Advanced Upper Gastrointestinal Tract Adenocarcinoma

EtrumadenantPhase 2

Prostatic Neoplasms, Castration-Resistant

AB680Phase 2

Metastatic Colorectal Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts